Runben Biotechnology (SH:603193) Xin Lang Zheng Quan·2025-10-31 01:29Core Viewpoint - Runben Co., Ltd. has shown a mixed performance in terms of stock trading and financial results, with significant fluctuations in financing activities and a notable increase in shareholder numbers, indicating potential investor interest and market volatility [1][2]. Financing Activities - On October 30, Runben Co., Ltd. experienced a financing buy-in of 4.78 million yuan, while financing repayments amounted to 10.72 million yuan, resulting in a net financing outflow of 5.94 million yuan [1]. - The total financing balance reached 314 million yuan, accounting for 11.58% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 300 shares were repaid, and 1,600 shares were sold short, with a total short sale value of 42,000 yuan, and the remaining short position stood at 9,100 shares, with a balance of 239,000 yuan, also above the 80th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Runben Co., Ltd. reported a revenue of 1.238 billion yuan, reflecting a year-on-year growth of 19.28%, while the net profit attributable to shareholders was 266 million yuan, showing a modest increase of 1.98% [2]. - The company has distributed a total of 316 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 26,200, a rise of 57.33%, while the average number of circulating shares per shareholder decreased by 36.44% to 3,948 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Guotai Consumption Preferred Stock and the entry of new shareholders such as Southern CSI 1000 ETF and ICBC Consumption Service Mixed A [3].